Developer docs
API playgroundTry for free, no card

Search company profiles

Arranta Bio

Full company profile

uuid0002c3b

Namestring
Arranta Bio
Legal namestring
Arranta Bio
Websiteurl
arrantabio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Arranta Bio is a United States-based contract development and manufacturing organization (CDMO) founded in 2019 and headquartered in Watertown, with 101–250 employees. The company was purpose-built to serve the microbiome and Live Biotherapeutic Products (LBP) segment, providing end-to-end process development, GMP manufacturing, and aseptic fill-finish for early- to late-stage clinical programs targeting novel biotherapeutics.

Following acquisition by Sweden-based Recipharm AB, Arranta now operates as Recipharm Advanced Bio (branded ReciBioPharm), broadening its modality footprint to include xRNA therapies (plasmid DNA, mRNA, lipid nanoparticles, including continuous manufacturing), viral vectors (AAV, lentivirus, oncolytic viruses), microbial and live biotherapeutic products, recombinant proteins, and GMP sterile fill-finish. The company differentiates via an integrated two-continent operating model, GMP-certified suites tailored to ATMPs, and a proprietary process platform branded Recimagine™ that combines continuous production, Process Analytical Technology (PAT), and a digital process simulator.

The business model is project- and program-based CDMO services revenue, with clinical and commercial manufacturing contracts, process-development fees, and increasingly platform/licensing income tied to Recimagine™ assets and inbound collaborations (University of Oxford, NewBiologix, LenioBio, Hongene Biotech). Customer concentration specifics are not disclosed, but the client base appears to be advanced-therapy biotech innovators seeking regulatory-grade manufacturing for hard-to-produce modalities. Strategic ownership sits with Recipharm AB following the integration of Arranta as its advanced-therapies arm.

Short descriptiontext

Arranta Bio is a Watertown, MA-based CDMO specializing in microbiome, live biotherapeutic, xRNA, viral vector, and recombinant protein manufacturing, now operating as Recipharm Advanced Bio serving advanced-therapy biotech innovators.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWatertown, United States
HQ citystring
Watertown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
advanced therapy CDMO, viral vector manufacturing, live biotherapeutic products, plasmid DNA manufacturing, GMP sterile fill-finish
Industry4 codes
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical CDMO Services
Social media profiles1 record
Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Arranta Bio (now Recipharm Advanced Bio) is a contract development and manufacturing organization (CDMO) providing end-to-end process development and GMP manufacturing services for advanced therapeutic medicinal products (ATMPs). Its service portfolio spans xRNA therapies, plasmid DNA, lipid nanoparticles, viral vectors, microbial and live biotherapeutic products, recombinant proteins, and sterile fill-finish, serving biopharma sponsors across two continents.

Differentiator
Functional benefit
Problem solved
Product and service9 records
1xRNA Therapies
CategoryAdvanced Therapy CDMO Services
Description

End-to-end contract development and GMP manufacturing services for xRNA-based therapeutics, including plasmid DNA production, xRNA synthesis, lipid nanoparticle (LNP) formulation, and continuous xRNA manufacturing. Targeted at biopharma developers of mRNA and next-generation RNA medicines.

2Plasmid DNA Manufacturing
CategoryAdvanced Therapy CDMO Services
Description

Contract development and GMP manufacturing of plasmid DNA used as a starting material for xRNA therapies and viral vector production. Serves gene therapy and xRNA therapeutic developers.

3Lipid Nanoparticle (LNP) Services
CategoryAdvanced Therapy CDMO Services
Description

Contract development and manufacturing of lipid nanoparticles for encapsulation and delivery of xRNA payloads. Targeted at sponsors developing RNA-based drugs and vaccines.

4Virus & Viral Vectors
CategoryAdvanced Therapy CDMO Services
Description

Contract development and GMP manufacturing of viral vectors including AAV and lentivirus assets, oncolytic and unique viruses, plus cell, bacteria and virus banking. Serves gene therapy developers.

5Cell, Bacteria & Virus Banking
CategoryAdvanced Therapy CDMO Services
Description

GMP-compliant cell, bacteria, and virus banking services to establish and store master and working banks used as starting materials for viral vector and advanced therapy manufacturing programs.

6Microbial & Live Biotherapeutic Products
CategoryAdvanced Therapy CDMO Services
Description

Contract process development and GMP manufacturing for microbial strains and live biotherapeutic products (LBPs). Targeted at microbiome therapeutic developers and biopharma sponsors advancing LBPs into clinical and commercial stages.

7Recombinant Proteins
CategoryAdvanced Therapy CDMO Services
Description

Contract development and GMP manufacturing of recombinant proteins using microbial expression systems. Serves biopharma developers of protein-based therapeutics.

8GMP Sterile Fill-Finish
CategoryAdvanced Therapy CDMO Services
Description

GMP-compliant sterile fill-finish services for advanced therapy drug products, providing final drug-product manufacturing capacity for clinical and commercial supply.

9Recimagine™ Continuous Production System
CategoryProprietary CDMO Technology Platform
Description

Proprietary continuous production platform within the Recimagine™ ecosystem that integrates unit operations to support continuous manufacturing of advanced therapies. Targeted at sponsors seeking reduced timelines and process intensification versus traditional batch manufacturing.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

One of the world's largest CDMOs offering biologics, cell and gene therapy, and microbial manufacturing. Comparable to Arranta across the biologics, viral vector, and microbial/LBP CDMO modalities it serves.

TypeBroad incumbent
Description

Major global CDMO with deep capabilities in biologics, viral vectors, and cell therapy, including fill-finish. Directly comparable to Arranta's end-to-end advanced therapy offering and large-scale GMP manufacturing footprint.

TypeBroad incumbent
Description

Large-scale biologics CDMO offering mammalian cell culture manufacturing and fill-finish. Comparable as a contract manufacturer of recombinant biologics, with similar client base in pharma and biotech.

TypeBroad incumbent
Description

Global CDMO with strong biologics, viral vector, and microbial fermentation capabilities, including live biotherapeutic manufacturing. A direct competitor for Arranta's recombinant protein and microbial/LBP contracts.

TypeDirect peer
Description

CDMO offering mammalian and microbial biologics, cell and gene therapy, and fill-finish. Closely comparable to Arranta's multi-modality, mid-size advanced therapy CDMO profile and includes former Cobra Biologics viral vector operations.

TypeBroad incumbent
Description

Leading global biologics CDMO with end-to-end development and manufacturing services. Comparable in offering recombinant protein, viral vector, and integrated drug substance / drug product services similar to Arranta's stack.

TypeBroad incumbent
Description

Operates a large pharma services / CDMO business including viral vector manufacturing (via Brammer Bio) and biologics. Competes with Arranta for advanced therapy and biologics manufacturing programs.

TypeDirect peer
Description

Specialist CDMO focused on viral vectors, vaccines, and oncolytic viruses for advanced therapies. Directly comparable to Arranta's viral vector and oncolytic virus modalities within the advanced therapy CDMO space.

TypeDirect peer
Description

European CDMO providing microbial fermentation, viral vector, and fill-finish services. Comparable to Arranta's microbial/LBP and viral vector capabilities, especially for early- to mid-stage advanced therapy clients.

TypeEmerging player
Description

Newer CDMO platform building integrated biologics, viral vector, and nucleic acid manufacturing capacity. Comparable as a multi-modality advanced therapy CDMO competing for similar biotech clients as Arranta.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arranta Bio

Biopharmaceutical CDMO Servicesarrantabio.com

Arranta Bio is a Watertown, MA-based CDMO specializing in microbiome, live biotherapeutic, xRNA, viral vector, and recombinant protein manufacturing, now operating as Recipharm Advanced Bio serving advanced-therapy biotech innovators.

What Arranta Bio does

Arranta Bio is a United States-based contract development and manufacturing organization (CDMO) founded in 2019 and headquartered in Watertown, with 101–250 employees. The company was purpose-built to serve the microbiome and Live Biotherapeutic Products (LBP) segment, providing end-to-end process development, GMP manufacturing, and aseptic fill-finish for early- to late-stage clinical programs targeting novel biotherapeutics.

Following acquisition by Sweden-based Recipharm AB, Arranta now operates as Recipharm Advanced Bio (branded ReciBioPharm), broadening its modality footprint to include xRNA therapies (plasmid DNA, mRNA, lipid nanoparticles, including continuous manufacturing), viral vectors (AAV, lentivirus, oncolytic viruses), microbial and live biotherapeutic products, recombinant proteins, and GMP sterile fill-finish. The company differentiates via an integrated two-continent operating model, GMP-certified suites tailored to ATMPs, and a proprietary process platform branded Recimagine™ that combines continuous production, Process Analytical Technology (PAT), and a digital process simulator.

The business model is project- and program-based CDMO services revenue, with clinical and commercial manufacturing contracts, process-development fees, and increasingly platform/licensing income tied to Recimagine™ assets and inbound collaborations (University of Oxford, NewBiologix, LenioBio, Hongene Biotech). Customer concentration specifics are not disclosed, but the client base appears to be advanced-therapy biotech innovators seeking regulatory-grade manufacturing for hard-to-produce modalities. Strategic ownership sits with Recipharm AB following the integration of Arranta as its advanced-therapies arm.

Arranta Bio firmographics

Firmographics
Name
Arranta Bio
Legal name
Arranta Bio
Website
https://arrantabio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
101–250 employees
Short description
Arranta Bio is a Watertown, MA-based CDMO specializing in microbiome, live biotherapeutic, xRNA, viral vector, and recombinant protein manufacturing, now operating as Recipharm Advanced Bio serving advanced-therapy biotech innovators.
Ownership category
akta.pro rank

Arranta Bio industry classification

Industry
Product category
Biopharmaceutical CDMO Services
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAD
Cell Banking & Viral Seed Services (MCB/WCB/VSB)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGAGAG
Fill-Finish & Aseptic Drug Product Manufacturing (Biologics/ATMP)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Advanced therapy CDMO
  • Viral vector manufacturing
  • Live biotherapeutic products
  • Plasmid DNA manufacturing
  • GMP sterile fill-finish

Where Arranta Bio is headquartered

Location

Headquarters

HQ city
Watertown
HQ country
United States
HQ region
North America

Markets served

Arranta Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Arranta Bio product offering

Product offering

Core offering

Arranta Bio (now Recipharm Advanced Bio) is a contract development and manufacturing organization (CDMO) providing end-to-end process development and GMP manufacturing services for advanced therapeutic medicinal products (ATMPs). Its service portfolio spans xRNA therapies, plasmid DNA, lipid nanoparticles, viral vectors, microbial and live biotherapeutic products, recombinant proteins, and sterile fill-finish, serving biopharma sponsors across two continents.

Differentiator

Problem solved

Functional benefit

Products and services

  • xRNA Therapies End-to-end contract development and GMP manufacturing services for xRNA-based therapeutics, including plasmid DNA production, xRNA synthesis, lipid nanoparticle (LNP) formulation, and continuous xRNA manufacturing. Targeted at biopharma developers of mRNA and next-generation RNA medicines.
  • Plasmid DNA Manufacturing Contract development and GMP manufacturing of plasmid DNA used as a starting material for xRNA therapies and viral vector production. Serves gene therapy and xRNA therapeutic developers.
  • Lipid Nanoparticle (LNP) Services Contract development and manufacturing of lipid nanoparticles for encapsulation and delivery of xRNA payloads. Targeted at sponsors developing RNA-based drugs and vaccines.
  • Virus & Viral Vectors Contract development and GMP manufacturing of viral vectors including AAV and lentivirus assets, oncolytic and unique viruses, plus cell, bacteria and virus banking. Serves gene therapy developers.
  • Cell, Bacteria & Virus Banking GMP-compliant cell, bacteria, and virus banking services to establish and store master and working banks used as starting materials for viral vector and advanced therapy manufacturing programs.
  • Microbial & Live Biotherapeutic Products Contract process development and GMP manufacturing for microbial strains and live biotherapeutic products (LBPs). Targeted at microbiome therapeutic developers and biopharma sponsors advancing LBPs into clinical and commercial stages.
  • Recombinant Proteins Contract development and GMP manufacturing of recombinant proteins using microbial expression systems. Serves biopharma developers of protein-based therapeutics.
  • GMP Sterile Fill-Finish GMP-compliant sterile fill-finish services for advanced therapy drug products, providing final drug-product manufacturing capacity for clinical and commercial supply.
  • Recimagine™ Continuous Production System Proprietary continuous production platform within the Recimagine™ ecosystem that integrates unit operations to support continuous manufacturing of advanced therapies. Targeted at sponsors seeking reduced timelines and process intensification versus traditional batch manufacturing.

Companies that use Arranta Bio

Customer profile

Ideal customer profiles1 record

Arranta Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Arranta Bio partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights4 records

Arranta Bio competitors and assessment

Company assessment

Broad incumbents

  • Lonza: One of the world's largest CDMOs offering biologics, cell and gene therapy, and microbial manufacturing. Comparable to Arranta across the biologics, viral vector, and microbial/LBP CDMO modalities it serves.
  • Catalent: Major global CDMO with deep capabilities in biologics, viral vectors, and cell therapy, including fill-finish. Directly comparable to Arranta's end-to-end advanced therapy offering and large-scale GMP manufacturing footprint.
  • Samsung Biologics: Large-scale biologics CDMO offering mammalian cell culture manufacturing and fill-finish. Comparable as a contract manufacturer of recombinant biologics, with similar client base in pharma and biotech.
  • FUJIFILM Diosynth Biotechnologies: Global CDMO with strong biologics, viral vector, and microbial fermentation capabilities, including live biotherapeutic manufacturing. A direct competitor for Arranta's recombinant protein and microbial/LBP contracts.
  • WuXi Biologics: Leading global biologics CDMO with end-to-end development and manufacturing services. Comparable in offering recombinant protein, viral vector, and integrated drug substance / drug product services similar to Arranta's stack.
  • Thermo Fisher Scientific (Patheon / Brammer Bio): Operates a large pharma services / CDMO business including viral vector manufacturing (via Brammer Bio) and biologics. Competes with Arranta for advanced therapy and biologics manufacturing programs.

Direct peers

  • AGC Biologics: CDMO offering mammalian and microbial biologics, cell and gene therapy, and fill-finish. Closely comparable to Arranta's multi-modality, mid-size advanced therapy CDMO profile and includes former Cobra Biologics viral vector operations.
  • Vibalogics: Specialist CDMO focused on viral vectors, vaccines, and oncolytic viruses for advanced therapies. Directly comparable to Arranta's viral vector and oncolytic virus modalities within the advanced therapy CDMO space.
  • Biovian: European CDMO providing microbial fermentation, viral vector, and fill-finish services. Comparable to Arranta's microbial/LBP and viral vector capabilities, especially for early- to mid-stage advanced therapy clients.

Emerging players

  • Resilience: Newer CDMO platform building integrated biologics, viral vector, and nucleic acid manufacturing capacity. Comparable as a multi-modality advanced therapy CDMO competing for similar biotech clients as Arranta.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Arranta Bio social profiles

Digital presence

Arranta Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arranta Bio leadership team

Management profile

Number of profiles

Profiles3 records

Arranta Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arranta Bio M&A and investment

M&A and investment

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arranta Bio

What does Arranta Bio do?

Arranta Bio (now Recipharm Advanced Bio) is a contract development and manufacturing organization (CDMO) providing end-to-end process development and GMP manufacturing services for advanced therapeutic medicinal products (ATMPs). Its service portfolio spans xRNA therapies, plasmid DNA, lipid nanoparticles, viral vectors, microbial and live biotherapeutic products, recombinant proteins, and sterile fill-finish, serving biopharma sponsors across two continents.

Is Arranta Bio a public or private company?

Arranta Bio is a private company. It is classified as corporate owned and is currently operating.

When was Arranta Bio founded?

Arranta Bio was founded in 2022. It employs 101 to 250 people.

Where is Arranta Bio based?

Arranta Bio is headquartered in Watertown, United States, in the North America region.

Who are Arranta Bio's main competitors?

Broad incumbents on record are Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, WuXi Biologics and Thermo Fisher Scientific (Patheon / Brammer Bio). Direct peers are AGC Biologics, Vibalogics and Biovian. Resilience is listed as an emerging player.

Does Arranta Bio have an API?

No public API is recorded for Arranta Bio.

What industry is Arranta Bio in?

Arranta Bio's product category is Biopharmaceutical CDMO Services. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of HLAGAGAD, Cell Banking & Viral Seed Services (MCB/WCB/VSB). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireUS Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Biosciences, Wacker Chemie, Quay Pharmaceuticals, NIZO, Lonza, Inpac ProbioticsThe U.S. live biotherapeutics market was valued at $44.64 million in 2024 and is projected to reach $97.91 million by 2030, a CAGR of 13.96%. Growth is driven by chronic disease prevalence and microbiome research, while regulatory uncertainty and lack of standardized guidelines pose challenges.GlobeNewswireUS Live Biotherapeutics Market Research 2025, Competitive Analysis of Arrant Bio, 4D Pharma, Cerbios, Biose, Assembly Biosciences, Wacker Chemie, Quay Pharmaceuticals, NIZO, Lonza, Inpac ProbioticsThe U.S. live biotherapeutics market was valued at $44.64 million in 2024 and is projected to reach $97.91 million by 2030, a CAGR of 13.96%. Growth is driven by chronic disease prevalence and microbiome research, while regulatory uncertainty and lack of standardized guidelines pose challenges.news.cision.comArranta Bio, a Recipharm company, signs contract with MIT to develop rapid manufacturing of mRNA therapeuticsArranta Bio, a Recipharm company, signed a contract with MIT to develop continuous manufacturing technology for mRNA therapeutics. The three-year project is part of the FDA's CBER initiative, one of the largest awards to MIT, aiming to enable faster response to pandemic threats and novel therapeutics.news.cision.comRecipharm’s Arranta Bio expands RNA process development capacity by 50 per cent to meet increased customer demandArranta Bio, a Recipharm company, expanded its RNA process development capacity by 50% at its Watertown, MA facility, adding about 2,000 ft2 of lab space. The expansion supports rapid scale-up to GMP manufacturing for mRNA and lipid nanoparticle therapies.PR NewswireNucleic Acid Therapeutics CDMO Market worth $4.69 Bn by 2030 - Exclusive Report by InsightAce AnalyticInsightAce Analytic released a market assessment report indicating the global nucleic acid therapeutics CDMO market is projected to grow from US$1.93 billion in 2021 to US$4.69 billion by 2030, at a CAGR of 10.7%. The report identifies key industry developments including strategic partnerships, acquisitions, and facility expansions by major players such as Merck partnering with Agilent Technologies on process analytics, Recipharm acquiring Arranta Bio, and CordenPharma investing over €10 million in xRNA capability expansion in Italy.MarketScreenerRecipharm AB acquired Arranta Bio Holdings, LLC from Ampersand Capital Partners and others.Recipharm AB has acquired Arranta Bio Holdings, LLC from Ampersand Capital Partners and other sellers. Recipharm is a Sweden-based pharmaceutical company operating as a Contract Development and Manufacturing Organization (CDMO). The acquisition expands Recipharm's capabilities in sterile product manufacturing.Drug Development and DeliveryRecipharm Announces Acquisition of Vibalogics & Arranta BioRecipharm announced the simultaneous acquisition of Vibalogics and Arranta Bio to expand its contract development and manufacturing organization (CDMO) capabilities in advanced therapy medicinal products. This strategic move integrates specialized virotherapy and microbiome/mRNA manufacturing expertise, strengthening Recipharm's presence in the US market. The transactions are expected to complete around the end of March 2022.PR NewswireInceptor Bio Announces Agreement to Acquire Gainesville, FL GMP Facility And Transfer Operating Team From Arranta Bio To Accelerate Cell Therapies To Cure CancerInceptor Bio announced an agreement to acquire a 29,000 ft² process development and GMP clinical manufacturing facility in Gainesville, FL from Arranta Bio, along with the transfer of a core operating team. The acquisition establishes Inceptor Bio's Advanced Manufacturing Platform (AMP+) to support cell and gene therapy clinical supply for its planned oncology trials, with the lead CAR-T candidate targeted for IND filing in early 2023. Arranta Bio, a contract development and manufacturing organization, conducted a strategic review and determined it could accommodate early clinical supply for its clients from its Massachusetts facilities.PR NewswireArranta Bio Announces First End-to-End Manufacturing for mRNA Vaccines in its Commercial-ready GMP FacilityArranta Bio announced plans to establish the first end-to-end contract manufacturing platform for mRNA vaccines at its commercial-ready GMP facility in Watertown, MA, integrating cGMP production of critical raw materials, in-vitro transcription, mRNA purification, lipid nanoparticle formulation, and sterile fill/finish within a single site. The company completed an 80,000 ft² facility in 2020 with Grade C clean rooms and plans to have drug substance process development capacity by end of 2021, GMP clinical manufacturing by early 2022, and integrated isolator technology operational in the second half of 2022. The platform is intended to support vaccine innovators developing prophylactic vaccines for infectious diseases as well as therapeutic cancer vaccines.